HCV In The News
Incivek/Telaprevir
Victrelis/Boceprevir
Telaprevir with VX-222
In the US Vertex will be calling Telaprevir "INCIVEK" in Europe it will be called "Incivo" and Mercks Boceprevir is registered as "VICTRELIS"
Both of the new medicines work by blocking a protein called protease that the virus needs to replicate
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
How Do I Take Incivek-telaprevir ?
Included in the information will be the dosing regimen for Incivek in combination with pegIFN/RBV, and a list of drugs that could cause drug interactions if used while taking the combo.
Updated Nov 16
All about HCV Genotypes and new possible therapies
Also;Investigational drugs in the treatment of genotype 4
Hepatitis C-New Protease Inhibitor (NS3/4A) Drug Resistance Test
Hepatitis C virus resistance to protease inhibitors
Patient video;New hepatitis C Drugs and Resistance
Hepatitis C: current management and emerging therapies
Archives 2011-2010
Telaprevir
Boceprevir
New Drug Pipeline
New drugs in development for the treatment of hepatitis C
Telaprevir FDA Approved
Oct 11
INCIVEK(TM) (telaprevir) Now Available in Canada
Sept 20
European approval for hepatitis C drug, Telaprevir-Incivek "called Incivo in Europe."
Health Canada Okays INCIVEK For People With Hepatitis C
FDA Approves Telaprevir/Incivek For Hepatitis C
Boceprevir FDA Approved
Nov 22
Ontario first province to reimburse new chronic hepatitis C treatment VICTRELIS™ Now Available for Eligible Patients in Ontario
The Canadian Liver Foundation is pleased that Ontario’s public drug program has agreed to reimburse boceprevir for the treatment of chronic hepatitis C,” says Dr. Morris Sherman, Chairman of the Canadian Liver Foundation. “Boceprevir represents a major advance in our ability to cure this disease, and as a result, fewer patients will have to struggle with the consequences of end-stage liver disease, liver transplants and liver cancer. We applaud the research efforts that led to this breakthrough and hope other provinces will follow Ontario’s lead and rapidly reimburse this important treatment.”
Health Canada Clears Victrelis-Boceprevir New Hepatitis C Drug
MSD launches hepatitis C drug Victrelis in UK
Vicrelis/Boceprevir IS NOW FDA Approved May 13 2011
Patient Assistance Program
INCIVEK/Telaprevir and VICTRELIS (Boceprevir) Patient Assistance Programs
Of Interest
Use of New HCV Protease Inhibitors ‘Not That Simple’
Incivek/Victrelis; New approvals may change treatment for hepatitis C
FYI-Which New Hepatitis C Drug do MDs Prefer? Incivek vs. Victrelis
New Treatments For Hepatitis C; Boceprevir vs Telaprevir: What We Know and Don't Know
Getting Ready; Telaprevir or Boceprevir?
Boceprevir-victrelis-Which pegylated interferon?
Worth Reading
FDA Transcripts Telaprevir/Boceprevir April Advisory Committee Meeting Includes Side Effects
Medication Guides;
Telaprevir/Incivek Prescribing Information
Medication Guide
VICTRELIS™- Boceprevir: Prescribing Information and Medication Guide
Peginterferon alfa
Ribavirin
Free from Hepatitis C:Your Complete Guide to Healing Hepatitis C (Dec 1, 2011 release); Click on the book to learn more.
- A Guide 2011-Management Of HCV (1)
- A-New targets for antiviral therapy (7)
- AASLD 2011 updated hepatitis C practice guidelines (2)
- AASLD 2012-STC (1)
- AASLD Nov 2011 (60)
- AASLD Nov 2011-Pocasts-Videos-Webcasts (1)
- AASLD Nov 2011-Summary (1)
- AASLD Oct2010 (80)
- AASLD Oct2010-summary (1)
- ABT-450 (4)
- Acai Berry Scam (1)
- ACH-1625 (10)
- ACH-2684 (2)
- ACH-2928 (2)
- ACH-3102 (1)
- ACLF (1)
- acute HCV (3)
- acute liver failure (1)
- addiction (8)
- Adherence to therapy (7)
- ADI-PEG 20 (1)
- AIDS (1)
- alisporivir (1)
- ALS-2200 and ALS-2158 (2)
- ANA598 (5)
- ANA598-setrobuvir (1)
- ANA773 (1)
- ANA958 (1)
- anemia (3)
- antidepressants (3)
- arthritis (2)
- ascites (3)
- asthma (1)
- autoimmune hepatitis (1)
- Avila Therapeutics™ (1)
- AVL-192 (2)
- bath salts-spice (6)
- Bavituximab (5)
- Behind the Headlines (1)
- Behind the Headlines-Vaccine (1)
- Best Hospitals (4)
- BI 201335 (13)
- BI 201335 and BI 207127 (3)
- BI 207127 (6)
- BILB 1941 (1)
- Bioartificial Liver (3)
- biological "devices" to program cells (1)
- BioScience (2)
- biosimilars (3)
- BIT225 (1)
- blood safety (1)
- blood scandal (3)
- bms-650032 (5)
- BMS-650032 (Asunaprevir) BMS-790052 (Daclatasvir) (1)
- BMS-650032 and BMS-790052 (4)
- bms-790052 (17)
- bms-790052-declatasvir (1)
- boceprevir (96)
- Boceprevir FDA Transcript (1)
- boceprevir patient guide (1)
- boceprevir-drug assistance program (3)
- boceprevir-Medication Guide-Prescribing Info (1)
- boceprevir-victrelis (69)
- boceprevir-victrelis-Cost (1)
- boceprevir-victrelis-mericitabine w-SOC (1)
- Bowel (1)
- Brain (2)
- Caleco Pharma (1)
- Canada (1)
- cancer (5)
- cancerous growths gallbladder and/or the bile duct (1)
- CDC (2)
- CDC- World Hepatitis Day 2011 (1)
- Chat room (3)
- children treating HCV (9)
- chronic disease (2)
- chronic fatigue (13)
- chronic hepatitis c (1)
- chronic liver failure (2)
- chronic pain (3)
- cirrhosis (106)
- clinical trials (66)
- clinical trials-Pro-Con (2)
- coffee (9)
- Colloidal silver (1)
- compensated cirrhosis (9)
- Complementary and Alternative Medicine (8)
- Counterfeit drugs (4)
- covalent inhibitor (2)
- Creating Functional Hepatic Tissue (1)
- Cryoglobulinemia (4)
- CTS-1027 (5)
- Daclatasvir/Asunaprevir (1)
- Daily Consensus Interferon (1)
- Danoprevir (7)
- DDW 2011 Meeting (11)
- DEB025 (2)
- DEB025- alisporivir (2)
- decompensated cirrhosis (15)
- Dental (2)
- Depression (7)
- diabetes (74)
- diabetes-insulin resistance (4)
- Digestion (1)
- Direct-acting Antivirals (6)
- disease progression (8)
- donation (5)
- drug alerts (1)
- Drug Assistance Programs (4)
- dry eye (1)
- EASL (60)
- EASL-Summary (1)
- ELAD® Bioartificial Liver (1)
- encephalopathy (16)
- endoscopy (1)
- Epidemic HCV (9)
- Epogen (3)
- ESLD (1)
- fatigue (4)
- Fatty Liver (66)
- FDA (52)
- fibromyalgia (4)
- Fluvastatin (1)
- Foodborne illness (11)
- G7128 (1)
- gallbladder (1)
- gallstones (7)
- Gastroenterologist (1)
- geno 2 (1)
- geno1 (55)
- geno2 (23)
- geno3 (32)
- geno4 (16)
- geno5 (3)
- geno6 (5)
- genotypes;All (10)
- green tea (1)
- GS-9190 (6)
- GS-9256 (5)
- Gut Bacteria (1)
- HALL OF SHAME (31)
- HALT-C (5)
- hav (5)
- hbv (63)
- HCV Australia (1)
- hcv abstracts (168)
- HCV Awareness (19)
- HCV Forum (1)
- HCV News (377)
- HCV pregnancy (5)
- HCV replication (3)
- HCV research (30)
- HCV Self-management (1)
- HCV symptoms (2)
- HCV tests (17)
- HCV tests-endoscope (1)
- HCV Vaccine (14)
- HCV vaccine GI-5005 (6)
- HCV Vaccine-TG4040 (MVA-HCV) (1)
- HCV Worldwide (21)
- HCV Worldwide Asia Australia Egypt (1)
- HCV Worldwide-Europe Canada Israel (1)
- HCV Your Health (3)
- HCV-Breast Cancer Risk (1)
- HCV-Editorial (1)
- HCV-Insulin resistance (2)
- HCV-Statins (1)
- HCV/HBV/HIV special populations (1)
- Health Reform (2)
- Health Reform-Insurance (2)
- Healthy you (14)
- hemochromatosis (1)
- Hepatitis-related Renal Disease (1)
- hepatologist (1)
- hepatoSys Virtual Liver Network (1)
- herb (26)
- herb-kava (1)
- HEV (2)
- History of HCV (3)
- HIV (74)
- HIV-children (1)
- HIV/HCV (36)
- hot topic (8)
- HTAs-host-targeting agents (1)
- human genome (5)
- human interferon alpha lozenges (1)
- Idenix Reports Positive Interim Data for Hepatitis C Drug (1)
- IDX184 (1)
- IDX184/on hold (2)
- IDX184/on hold-removed (1)
- IDX320/pulled (2)
- if I had.. (9)
- IL-7(CYT 107) (1)
- IL28B (39)
- IL28B Test (1)
- immune system (8)
- IMO-2125 (6)
- Inflammation (1)
- Inflammation Liver (1)
- Inflammatory Bowel Disease (1)
- Inspirational (23)
- Insurance (1)
- Insurance medicare (1)
- Interferon Free Combinations (34)
- Interferon lambdas (1)
- Investment News HCV Drugs (22)
- INX 189 (12)
- IP-10 (1)
- ITX-5061 (1)
- Joint pain (1)
- Just for fun (2)
- JX594/TG6006 (1)
- Lambda (1)
- Lichen Planus (3)
- List Peer-Reviewed Journals (1)
- Liver Abscess (2)
- liver biopsy (9)
- liver biopsy-necessary in all genotypes? (1)
- liver cancer (128)
- Liver cancer CF102 (2)
- Liver Cancer Treatment (60)
- liver cancer treatment-radiofrequency ablation (RFA) (1)
- Liver Cancer-HEAT Study of ThermoDox(R) (1)
- liver cancer-MCT-465 and MCT-485 (1)
- liver cancer/sorafenib (1)
- Liver Cysts (1)
- liver disease (4)
- Liver Fibrosis (52)
- liver function tests (10)
- liver health (54)
- Liver Injury Dietary Supplements (1)
- Liver Pain (6)
- liver surgery (2)
- locteron (1)
- Locteron/interferon (2)
- lymphoma (2)
- M11-602 (1)
- marijuana (20)
- marijuana-based prescription drug (1)
- Men and HCV (2)
- microspheres (3)
- Milk thistle (15)
- Miravirsen (2)
- MK-5172 (1)
- MK-7009 (1)
- Morbidity-SVR (1)
- Mortality (6)
- myocarditis (1)
- nanoparticles (2)
- Nanotechnology (1)
- Natural leukocyte interferon alpha (Alfaferone) (1)
- Neutropenia HCV Treatment (3)
- new drugs (1)
- new hcv drugs (55)
- newly diagnosed (6)
- newsletters (27)
- Nitazoxanide (1)
- noninvasive tests for fibrosis (24)
- nonresponders (6)
- NSAID (5)
- null responders (8)
- Off Topic (25)
- organ harvesting (7)
- organ trafficking (3)
- organ trafficking- U.S (1)
- Other Conditions Related To HCV (38)
- Other Conditions Related To HCV-Vasculitis (3)
- Other Health News (66)
- OTHER INFECTIOUS DISEASE (19)
- outsourcing clinical trials (3)
- outsourcing drugs (7)
- partial responders (3)
- Pediatric liver disease (1)
- Pegasys (8)
- Peginterferon (54)
- PegIntron (4)
- Peripheral Neuropathy (1)
- PF-05095808 (1)
- Pharmaceuticals (48)
- platelets (1)
- polymerase inhibitor (11)
- Porphyria Cutanea Tarda (PCT) (1)
- Post Treatment Symptoms (1)
- PPI-461 (3)
- PPI-668 (2)
- primary biliary cirrhosis (PBS) (1)
- probiotics (1)
- procrit (4)
- prognostic test:response to therapy (1)
- prostate cancer (1)
- protease inhibitor (23)
- protease inhibitor- (NS3/4A) Drug Resistance Test (2)
- PSI-7977 (25)
- PSI-7977 and PSI-938 (1)
- PSI-7977-TMC435 (2)
- PSI-7977/ Daclatasvir-(BMS-790052) (1)
- PSI-938 (6)
- PSI-938-Halted (1)
- Pulmonary fibrosis (1)
- Quackery (9)
- Questions About HCV (4)
- rash (6)
- recall (19)
- regeneration (4)
- regenerative Medicine (10)
- relapse (3)
- resistance to protease inhibitors (12)
- response-guided therapy (1)
- RG7128 (9)
- ribavirin (15)
- Ritonavir (1)
- rituximab (2)
- salt (4)
- scientists grow human livers in laboratory (7)
- SCY-641 (1)
- Seasonal Flu Vaccine (3)
- selenium (1)
- setrobuvir (1)
- side effects (49)
- side effects-direct-acting antivirals (5)
- side effects-eyes (4)
- side effects-telaprevir (1)
- silymarin (1)
- SIR-Spheres microspheres (2)
- Small fiber neuropathy (2)
- Sorafenib (2)
- SPC3649-(Miravirsen) (1)
- sphincter of Oddi (3)
- spleen (5)
- SPONTANEOUS CLEARANCE (8)
- Starting HCV Treatment (46)
- STAT-C (3)
- stem cell tourism (5)
- stem cell-diabetes (1)
- stem cells (50)
- stem cells-pluripotent (2)
- supplements (6)
- support (19)
- Surgery in liver disease (1)
- svr (47)
- SVR-Mortality (1)
- svr-pitavastatin (Livalo) (1)
- svr-rapid response (1)
- Tattoos (1)
- telaprevir (121)
- Telaprevir FDA Transcript (1)
- telaprevir medication guide (1)
- telaprevir patient assistance (3)
- telaprevir prescribing information (1)
- telaprevir with VX-222 (14)
- telaprevir-incivek (83)
- telaprevir-incivek-Cost (2)
- Tenofovir (2)
- Terry's nails (1)
- TG4040 (1)
- Thalidomide (1)
- Therapy-over the age of 65 (1)
- TheraSphere (1)
- Thrombocytopenia (2)
- thrombosis (2)
- thyroid (7)
- Timeline Hepatiits (1)
- TMC278 for HIV (1)
- TMC435 (20)
- TMC435-BMS-790052 (1)
- TMC649128 (4)
- toxicity (21)
- transmission (44)
- Transmission clinical setting (36)
- Transmission of HCV Through Transplanted Organs (1)
- transmission-needlestick (1)
- transplant (107)
- transplant tourism (7)
- transplant-HCV recurrence (1)
- transplant-IL28B (1)
- transplant-MELD (4)
- Triad Prep Pads (14)
- tylenol (2)
- upper abdominal pain (1)
- varices (12)
- video (204)
- video viral load test(PCR) (1)
- viral load (6)
- Virtual Liver (1)
- virus research (2)
- vitamin A (1)
- vitamin B12 (1)
- vitamin D (24)
- vitamin E (4)
- vitamin k (1)
- vitamins (4)
- wellness (52)
- what is hepatitis c (1)
- women (5)
- Xifaxan (1)
- zalbin (1)
Part One: Hey Can I Get Hepatitis C From......
Part Two: Hey, I Have A Question About HCV Tests
Part Three : Hey,I Have Questions About Cirrhosis And My Liver......
Part Four: Thirty Eight Questions About Hepatitis C
Part Five: Hey, I have a question about this IL28B gene and hepatitis c treatment.....
Part Six: Do I still need a liver biopsy? What Is A Noninvasive Test For Fibrosis ?
Treatment Side Effects
Skin Rash During Chronic Hepatitis C Therapy
HCV Treatment and Neutropenia(low white count)
Older HCV Patients Have More Side Effects
Chronic cough/Pegylated interferon/ribavirin In HCV Therapy
Interferon-α induced severe thrombocytopenia: A case report and review of the literature
Other HCV Sites:
These links will take you to the premier Hepatitis C sites and keep you informed with breaking news, clinical studies, new drugs, podcasts, newsletters, support, personal experiences, chat rooms, forums and more.
AASLD
The American Association for the Study of Liver Diseases November 2011 Annual Meeting
AASLD-Liver Learning
If you haven't yet explored the "Liver Learning" section available @ the AASLD web site you're missing out on the November meeting webcasts, video podcasts, abstracts and more.
Web Site
AASLD Coverage Available On The Web Site
This AASLD Summary attempts to present recent data in an accessible format providing a greater understanding of current and future gentler HCV therapies that could be available in the near future.
Included are many of the investigational second-generation protease inhibitors and Interferon-free treatment regimens presented at this months meeting.
-
▼
2012
(121)
-
▼
February 2012
(8)
- Hepatitis News Ticker Friday Round Up-IDX184 Remov...
- What is Killing People With Hepatitis C Virus Infe...
- Bacterial imbalance may be behind liver disease
- Strategies for Success: Management of Telaprevir-A...
- Coffee consumption reduces the risk of advanced fi...
- Roundwood Doctor Nicola leads Hepatitis C reseach
- Hepatitis C-What A Pain-Liver Pain!
- Hepatitis News Ticker: Anemia During HCV Therapy -...
-
►
January 2012
(113)
- Video-New and experimental oral drugs to treat hep...
- Hepatitis C Drug Victrelis-Boceprevir released for...
- Stem cells may shed light on hepatitis C, MIT rese...
- Hepatitis C News Ticker: The ELF test-Blood Test I...
- The Effect of Caffeine and Alcohol Consumption on ...
- Fatigue in Cirrhosis: Is Transplant the Answer?
- The phenotypic fate and functional role for bone m...
- Hepatitis C-Clinical evidence for the regression o...
- Why Boomers Should Be Aware of Hepatitis
- Once-weekly diabetes drug wins approval on third t...
- Muscle and Mortality in Cirrhosis
- The 2012 AASLD Hepatitis Single Topic Conference (...
- Friday Round Up - Hepatitis News Ticker:
- Entry point of hepatitis C virus identified
- Germany’s IQWiG sees added benefits for Incivo
- Big Pharma:The Hepatitis C Race For Tolerable Ther...
- Pharmasset's Hepatitis C Drug: How it Could Change...
- Watch-Beware of Hepatitis B at the nail salon
- Magic mushrooms point to new depression drugs
- Pot-based prescription drug looks for FDA OK
- Drop in effectiveness of HCV treatment in national...
- New Hepatitis C Regimen Stimulates Changes in Ther...
- Your liver is for life - so treat it well
- Hepatitis C Virus Infection In Non-Hodgkin’s Lymph...
- Off Topic- 6 Devices That Could Change the Standar...
- Dietary Fiber for the Treatment of Type 2 Diabetes...
- Editorial-How to Optimize Treatment of Hepatitis C...
- Surveillance for Hepatocellular Carcinoma in Patie...
- Diabetes-Biochip measures glucose in saliva, not b...
- Gender Differences in Liver Cancer Risk Explained ...
- Hepatitis C Friday News Ticker: How far is noninva...
- Hepatitis C-From Clinical Guidelines to Clinical P...
- New developments in HCV therapy
- How far is noninvasive assessment of liver fibrosi...
- Steatosis and insulin resistance in response to tr...
- Yes! Statins can be given to liver patients
- Risk factors for hepatocellular carcinoma in diabe...
- Achillion's Hep C Pipeline Likely Can't Compete
- Daclatasvir and Asunaprevir:New Drug Combo for Hep...
- U.S. Food and Drug Administration Approves New For...
- Boceprevir and telaprevir for hepatitis C: safety ...
- Factors linked to severe thrombocytopenia during a...
-
▼
February 2012
(8)
-
►
2011
(1577)
- ► December 2011 (75)
- ► November 2011 (81)
- ► October 2011 (70)
- ► September 2011 (83)
- ► August 2011 (142)
- ► April 2011 (161)
- ► March 2011 (176)
- ► February 2011 (140)
- ► January 2011 (199)
-
►
2010
(677)
- ► December 2010 (186)
- ► November 2010 (236)
- ► October 2010 (226)
- ► September 2010 (29)
GET TESTED
Click here to order a FREE Home Access Hepatitis C Test Kit
How Soon Should I Get Tested After Exposure ?
After the exposure (especially if the blood exposure involved another person known to have the hepatitis C virus), it is recommended that testing for the hepatitis C antibody be performed at 4 to 6 months after the exposure OR that testing for the hepatitis C virus itself (a test often called an HCV PCR or hepatitis C viral load test) be performed 4 to 6 weeks after the potential exposure. These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure.;
FAIR USE NOTICE:
If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas. It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes. The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice
- New HCV Drugs
- Keeping current on the potential arrival of new, improved Hepatitis C drugs is a regular research venture for many who are living with the Hepatitis C virus. I was 43, a mother of three when I found out I had HCV. I went on to be treated successfully in 2000.(Intron A/Riba). Only people who have experienced a chronic illness understand the fear and apprehension felt with each step up the ladder, climbing closer to either medical treatment or a possible cure. These millions of people (I was one of them) who are living with chronic hepatitis C or just newly diagnosed are often left out in the cold, alone, with many unanswered questions. Enter the sleepless nights, anxiety, waking each day wondering what to do next. My blog is here to help you learn about HCV, the new drugs to treat this disease along with news and updates. Wishing you all a safe journey. Tina
